XNASTSVT
Market cap134mUSD
Jan 17, Last price
2.61USD
1D
6.97%
1Q
-47.70%
IPO
-90.21%
Name
2Seventy Bio Inc
Chart & Performance
P/E
—
P/S
1.34
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
16.17%
Rev. gr., 5y
12.96%
Revenues
100m
+9.72%
Net income
-218m
L-14.39%
CFO
-167m
L-29.64%
Earnings
Mar 03, 2025
Profile
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 100,387 9.72% | 91,496 67.81% | ||||
Cost of revenue | 247,676 | 274,954 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (147,289) | (183,458) | ||||
NOPBT Margin | ||||||
Operating Taxes | (9) | |||||
Tax Rate | ||||||
NOPAT | (147,289) | (183,449) | ||||
Net income | (217,570) -14.39% | (254,144) -7.99% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 126,863 | 165,533 | ||||
BB yield | -60.29% | -49.57% | ||||
| Debt | ||||||
Debt current | 25,320 | 11,164 | ||||
Long-term debt | 744,699 | 529,180 | ||||
Deferred revenue | 3,918 | 5,000 | ||||
Other long-term liabilities | (241,597) | 2,397 | ||||
Net debt | 548,214 | 272,660 | ||||
| Cash flow | ||||||
Cash from operating activities | (166,858) | (237,134) | ||||
CAPEX | (13,865) | (22,842) | ||||
Cash from investing activities | 43,861 | 11,697 | ||||
Cash from financing activities | 127,390 | 166,229 | ||||
FCF | (128,777) | (169,622) | ||||
| Balance | ||||||
Cash | 216,989 | 266,270 | ||||
Long term investments | 4,816 | 1,414 | ||||
Excess cash | 216,786 | 263,109 | ||||
Stockholders' equity | (511,416) | (296,520) | ||||
Invested Capital | 1,286,396 | 884,555 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 49,276 | 35,637 | ||||
Price | 4.27 -54.43% | 9.37 -63.44% | ||||
Market cap | 210,409 -36.99% | 333,919 -44.76% | ||||
EV | 758,623 | 606,579 | ||||
EBITDA | (137,004) | (171,925) | ||||
EV/EBITDA | ||||||
Interest | 8,514 | |||||
Interest/NOPBT | ||||||